Domestic price of tucatinib/tucatinib

Tucatinib/Tucatinib is an oral small molecule drug that specifically targets human epidermal growth factor receptor 2 (HER2). It is mainly used to treat HER2-positive advanced or metastatic breast cancer and unresectable or metastatic colorectal cancer.

HER2, also known as Human Epidermal growth factor Receptor 2, is an important protein involved in cell growth and development. However, in some breast cancer patients, HER2 activity is abnormally increased. This condition is called HER2-positive breast cancer and accounts for about 20% of breast cancer patients. HER2-positive breast cancer is often more aggressive and has a higher rate of recurrence. The mechanism of action of tucatinib is to inhibit the activity of HER2, block its signaling to cancer cells, and further inhibit the growth and spread of cancer cells. In addition, tucatinib can also penetrate the blood-brain barrier and inhibit the metastasis of HER2-positive breast cancer in the brain. This property gives it a unique advantage in the treatment of patients with metastatic HER2-positive cancer.

Tucatinib is often combined with other anticancer drugs such as trastuzumab and chemotherapy drugs to enhance the effectiveness of the treatment. Clinical studies have shown that tucatinib combined with trastuzumab and chemotherapy can significantly extend the survival of patients with HER2-positive breast cancer compared with trastuzumab and chemotherapy alone. However, tucatinib also has some side effects, including diarrhea, vomiting, fatigue, rash, etc. Therefore, when using tucatinib, patients need to be closely monitored for side effects and adjusted and managed according to their doctor's recommendations.

The original drug Tucatinib is not on the domestic market, so its domestic price cannot be known. Currently, tucatinib is only available in certain overseas countries. For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.